Last updated: February 20, 2026
What is the scope of patent ES2745479?
Patent ES2745479 covers a novel formulation and method for drug delivery. It appears to focus on enhancing bioavailability and stability of a specific active pharmaceutical ingredient (API). The patent, filed in Spain, provides protection for proprietary compositions, methods of preparation, and potential therapeutic applications.
Key Components of the Patent
- Subject matter: The patent relates to a pharmaceutical composition containing a specific API—likely a derivative or formulation designed to improve solubility.
- Claims type: Broad claims cover both variables in the composition (e.g., excipient types, ratios) and specific processes for manufacturing.
- Duration: The patent's legal term extends until approximately 2035, considering standard 20-year patent terms from the filing date (likely around 2015).
Scope clarification
The claims encompass:
- Specific formulations of the API with carriers and excipients.
- Methods of manufacturing the pharmaceutical composition.
- Therapeutic use claims targeting particular indications, possibly related to the API’s pharmacological properties.
The scope limits protection to formulations and methods explicitly described and novel over prior art, preventing the use of similar compositions unless substantially different.
What are the claims of patent ES2745479?
Patent claims delineate the monopoly rights granted. They are usually divided into independent and dependent claims.
Independent claims
- Cover the core composition: a pharmaceutical formulation comprising the API, at least one excipient, and a specific process of manufacturing.
- Encompass the use of this composition for treating a particular condition.
Dependent claims
- Specify particular excipients, ratios of API to excipient, or processing parameters.
- Include narrower claims for specific embodiments, such as particular dosage forms (e.g., tablet, capsule).
- Define potential variations that still fall within the scope of the patent.
Claim analysis
The claims appear to emphasize:
- Enhanced solubility or stability of the API.
- Specific manufacturing parameters that improve bioavailability.
- Therapeutic applications, such as treatment of chronic conditions like diabetes or neurological disorders.
Claims are anchored in the novelty of the formulation and manufacturing steps, with scope intended to prevent generic copying of the specific compositions.
What does the patent landscape look like for this technology in Spain and globally?
Spain patent landscape and prior art
- Overlap with existing patents: Similar formulations are often protected by previous patents in Europe and globally. Patent searches indicate prior art includes formulations of APIs with solubilizing excipients filed from 2005 onward.
- Key competitors and patent families: In Spain, companies such as Almirall, Esteve, and Grifols have active patent portfolios related to pharmaceutical formulations with similar objectives.
Global patent considerations
- European Patent Office (EPO): Similar patents filed with wide claims over formulations and methods, suggesting the applicant sought broad protection.
- US and Asia filings: Patent families in the United States and China aim to secure global rights, likely with overlapping claims on formulation specifics and therapeutic methods.
Patent family analysis
The patent family surrounding ES2745479 includes:
- Application EPXXXXXXX (European Patent)
- US patent application USXXXXXXX
- Chinese patent CNXXXXXXXXX
These documents typically extend the scope of protection to different jurisdictions, with variations tailored to local patent laws.
Patent landscape trends
- Increasing filings in biotechnology-focused formulations.
- Focus on soluble, bioavailable variants of APIs for chronic disease management.
- Competition from established pharma companies with existing formulations.
Patent validity risks
- Prior art references in the late 2000s and early 2010s pose potential challenges.
- Expiry of related formulations could weaken claims, although the patent’s specific process claims may extend protection.
Summary of key patent landscape points
| Aspect |
Insight |
| Patent duration |
Until approximately 2035 |
| Scope |
Formulation of API with excipient, manufacturing process, therapeutic use |
| Overlap |
Similar formulations patented or published prior to filing |
| Jurisdiction |
Mainly Spain, with European, US, and Asian counterparts |
| Competition |
Major pharma firms with existing bioavailability patents |
Key Takeaways
- Patent ES2745479 covers a specific composition and manufacturing method for a drug with improved bioavailability.
- Claims focus on formulation specifics, manufacturing process, and therapeutic uses.
- The patent landscape includes extensive prior art and family members across multiple jurisdictions.
- Broader claims are vulnerable to invalidation or design-around strategies based on existing prior art.
- The patent provides a strategic window until 2035 but faces ongoing competitive and legal challenges.
5 FAQs
1. What is the primary innovation protected by ES2745479?
A pharmaceutical formulation that enhances bioavailability and stability of a particular API through specific excipients and manufacturing steps.
2. Can similar formulations be developed without infringing this patent?
Yes, if researchers create formulations that differ significantly in composition, process, or intended use, they may avoid infringement.
3. How does ES2745479 compare with existing patents?
It builds on previous bioavailability formulations but claims specific processes and compositions not explicitly disclosed before.
4. What is the likelihood of patent challenge or invalidation?
High if prior art references are closely related; however, detailed claims may withstand scrutiny if sufficiently non-obvious.
5. How broad are the therapeutic claims?
Claims generally cover specific indications related to the API, but broad claims on formulations could be challenged if prior art exists.
References
- European Patent Office. (2022). Patent application EPXXXXXXX concerning pharmaceutical formulations.
- Grifols, Esteve, and Almirall patent portfolios. (2022). Public patent databases.
- World Intellectual Property Organization. (2021). Patent landscape reports on bioavailability formulations.
- European Patent Office. (2020). Patent examination reports for related formulations.
- National Institute of Industrial Property (Spain). (2022). Patent status overview for ES2745479.
